Amarin Corp Plc (AMRN)

[Thonn]

But... assuming that the only limitation on generics is supply, then this price reduction you mention just gets that bottle of generic sold to a person from another insurer, and Amarin is reducing their income and benefits in these " new" sales. So, the new sales achieved here imply, on the other hand, that the generic bottles that are no longer sold at CVS are going to be sold at other insurers. The summary is that the number of Vascepa scripts does not increase... and Vascepa is sold cheaper, obtaining less margin from each sale. I'm not sure if the price reduction is the solution.